The burgeoning landscape of novel treatments for metabolic management has seen the here rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting considerable weight loss – they exhibit intriguing difference